Logo image of APS.CA

APTOSE BIOSCIENCES INC (APS.CA) Stock Overview

TSX:APS - CA03835T4081 - Common Stock

1.65 CAD
+0.01 (+0.61%)
Last: 9/5/2025, 7:00:00 PM

APS.CA Key Statistics, Chart & Performance

Key Statistics
52 Week High17.4
52 Week Low1.02
Market Cap4.21M
Shares2.55M
Float2.04M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-65.17
PEN/A
Fwd PEN/A
Earnings (Next)11-06 2025-11-06/amc
IPO06-04 1993-06-04
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


APS.CA short term performance overview.The bars show the price performance of APS.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

APS.CA long term performance overview.The bars show the price performance of APS.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of APS.CA is 1.65 CAD. In the past month the price decreased by -4.62%. In the past year, price decreased by -89.42%.

APTOSE BIOSCIENCES INC / APS Daily stock chart

APS.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
EDT.CA SPECTRAL MEDICAL INC N/A 465.89M
FRX.CA FENNEC PHARMACEUTICALS INC N/A 345.09M
EPRX.CA EUPRAXIA PHARMACEUTICALS INC N/A 265.03M
TH.CA THERATECHNOLOGIES INC N/A 208.29M
HBP.CA HELIX BIOPHARMA CORP N/A 110.75M
WLLW.CA WILLOW BIOSCIENCES INC N/A 97.56M
MDNA.CA MEDICENNA THERAPEUTICS CORP N/A 87.58M
BLU.CA BLUENERGIES LTD N/A 84.96M
MSCL.CA SATELLOS BIOSCIENCE INC N/A 66.23M
NRX.CA NUREXONE BIOLOGIC INC N/A 64.81M
COV.CA COVALON TECHNOLOGIES LTD 17.54 62.52M
SVA.CA SERNOVA BIOTHERAPEUTICS INC N/A 51.14M

About APS.CA

Company Profile

APS logo image Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. The company is headquartered in Toronto, Ontario and currently employs 13 full-time employees. The Company’s lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. The firm's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of anti-cancer therapies and regimens without overlapping toxicities. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.

Company Info

APTOSE BIOSCIENCES INC

66 Wellington Street West, Suite 5300,, TD Bank Tower Box 48

TORONTO ONTARIO M2J 4R3 CA

CEO: William G. Rice

Employees: 13

APS Company Website

APS Investor Relations

Phone: 18589262730

APTOSE BIOSCIENCES INC / APS.CA FAQ

What is the stock price of APTOSE BIOSCIENCES INC today?

The current stock price of APS.CA is 1.65 CAD. The price increased by 0.61% in the last trading session.


What is the ticker symbol for APTOSE BIOSCIENCES INC stock?

The exchange symbol of APTOSE BIOSCIENCES INC is APS and it is listed on the Toronto Stock Exchange exchange.


On which exchange is APS.CA stock listed?

APS.CA stock is listed on the Toronto Stock Exchange exchange.


What is the price forecast or stock price prediction for APTOSE BIOSCIENCES INC stock?

7 analysts have analysed APS.CA and the average price target is 136.76 CAD. This implies a price increase of 8188.55% is expected in the next year compared to the current price of 1.65. Check the APTOSE BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is APTOSE BIOSCIENCES INC worth?

APTOSE BIOSCIENCES INC (APS.CA) has a market capitalization of 4.21M CAD. This makes APS.CA a Nano Cap stock.


How many employees does APTOSE BIOSCIENCES INC have?

APTOSE BIOSCIENCES INC (APS.CA) currently has 13 employees.


What are the support and resistance levels for APTOSE BIOSCIENCES INC (APS.CA) stock?

APTOSE BIOSCIENCES INC (APS.CA) has a support level at 1.58 and a resistance level at 1.73. Check the full technical report for a detailed analysis of APS.CA support and resistance levels.


Should I buy APTOSE BIOSCIENCES INC (APS.CA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does APTOSE BIOSCIENCES INC (APS.CA) stock pay dividends?

APS.CA does not pay a dividend.


When does APTOSE BIOSCIENCES INC (APS.CA) report earnings?

APTOSE BIOSCIENCES INC (APS.CA) will report earnings on 2025-11-06, after the market close.


What is the Price/Earnings (PE) ratio of APTOSE BIOSCIENCES INC (APS.CA)?

APTOSE BIOSCIENCES INC (APS.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-65.17).


APS.CA Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to APS.CA. When comparing the yearly performance of all stocks, APS.CA is a bad performer in the overall market: 98.95% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

APS.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to APS.CA. Both the profitability and financial health of APS.CA have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

APS.CA Financial Highlights

Over the last trailing twelve months APS.CA reported a non-GAAP Earnings per Share(EPS) of -65.17. The EPS increased by 79.6% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -327.57%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%96.91%
Sales Q2Q%N/A
EPS 1Y (TTM)79.6%
Revenue 1Y (TTM)N/A

APS.CA Forecast & Estimates

7 analysts have analysed APS.CA and the average price target is 136.76 CAD. This implies a price increase of 8188.55% is expected in the next year compared to the current price of 1.65.


Analysts
Analysts82.86
Price Target136.76 (8188.48%)
EPS Next Y95.27%
Revenue Next YearN/A

APS.CA Ownership

Ownership
Inst Owners6.22%
Ins Owners0.32%
Short Float %N/A
Short RatioN/A